Agenus (AGEN) Competitors $3.66 -0.17 (-4.44%) Closing price 04:00 PM EasternExtended Trading$3.72 +0.05 (+1.50%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AGEN vs. XOMA, VNDA, VSTM, SGMO, LXRX, ACHV, RGLS, FBIO, SABS, and CRISShould you be buying Agenus stock or one of its competitors? The main competitors of Agenus include XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), Regulus Therapeutics (RGLS), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), and Curis (CRIS). These companies are all part of the "biotechnology" industry. Agenus vs. XOMA Vanda Pharmaceuticals Verastem Sangamo Therapeutics Lexicon Pharmaceuticals Achieve Life Sciences Regulus Therapeutics Fortress Biotech SAB Biotherapeutics Curis Agenus (NASDAQ:AGEN) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends, profitability and community ranking. Do analysts prefer AGEN or XOMA? Agenus currently has a consensus target price of $10.00, indicating a potential upside of 173.22%. XOMA has a consensus target price of $81.50, indicating a potential upside of 212.86%. Given XOMA's stronger consensus rating and higher probable upside, analysts clearly believe XOMA is more favorable than Agenus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agenus 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17XOMA 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, AGEN or XOMA? XOMA has lower revenue, but higher earnings than Agenus. XOMA is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgenus$156.31M0.55-$245.76M-$11.24-0.33XOMA$4.76M64.47-$40.83M-$3.48-7.49 Does the media prefer AGEN or XOMA? In the previous week, Agenus had 1 more articles in the media than XOMA. MarketBeat recorded 4 mentions for Agenus and 3 mentions for XOMA. Agenus' average media sentiment score of 0.52 beat XOMA's score of 0.34 indicating that Agenus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XOMA 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is AGEN or XOMA more profitable? Agenus has a net margin of -145.89% compared to XOMA's net margin of -151.34%. Agenus' return on equity of 0.00% beat XOMA's return on equity.Company Net Margins Return on Equity Return on Assets Agenus-145.89% N/A -85.68% XOMA -151.34%-24.95%-9.64% Which has more volatility & risk, AGEN or XOMA? Agenus has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, XOMA has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Do institutionals & insiders hold more shares of AGEN or XOMA? 61.5% of Agenus shares are owned by institutional investors. Comparatively, 95.9% of XOMA shares are owned by institutional investors. 4.6% of Agenus shares are owned by company insiders. Comparatively, 7.2% of XOMA shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor AGEN or XOMA? Agenus received 29 more outperform votes than XOMA when rated by MarketBeat users. Likewise, 69.19% of users gave Agenus an outperform vote while only 65.96% of users gave XOMA an outperform vote. CompanyUnderperformOutperformAgenusOutperform Votes46769.19% Underperform Votes20830.81% XOMAOutperform Votes43865.96% Underperform Votes22634.04% SummaryAgenus and XOMA tied by winning 9 of the 18 factors compared between the two stocks. Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGEN vs. The Competition Export to ExcelMetricAgenusBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.86M$3.01B$5.39B$9.24BDividend YieldN/A1.89%5.37%3.99%P/E Ratio-0.3345.9289.1117.52Price / Sales0.55275.981,221.8479.25Price / CashN/A189.5243.6036.96Price / Book-0.474.045.014.72Net Income-$245.76M-$40.99M$117.81M$224.61M7 Day Performance15.46%2.03%2.03%1.55%1 Month Performance29.33%1.50%4.03%5.12%1 Year Performance-68.90%-1.33%26.78%21.25% Agenus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGENAgenus3.734 of 5 stars$3.66-4.4%$10.00+173.2%-66.9%$85.86M$156.31M-0.33440Analyst ForecastNews CoverageHigh Trading VolumeXOMAXOMA4.178 of 5 stars$26.76-1.9%$81.50+204.6%+35.6%$315.23M$4.76M-7.6910VNDAVanda Pharmaceuticals4.0577 of 5 stars$4.36-1.8%$15.50+255.5%+23.2%$254.23M$192.64M-15.57290Analyst ForecastVSTMVerastem2.7783 of 5 stars$5.33+0.9%$13.38+150.9%-51.7%$237.24M$2.60M-1.6750SGMOSangamo Therapeutics2.7906 of 5 stars$1.09-0.9%$5.50+404.6%+161.5%$227.43M$176.23M-1.45480LXRXLexicon Pharmaceuticals1.8438 of 5 stars$0.69-3.3%$6.00+769.6%-39.4%$169.91M$1.20M-0.92140News CoverageACHVAchieve Life Sciences1.701 of 5 stars$3.09+0.7%$14.80+379.0%-36.9%$106.27MN/A-2.7320News CoverageRGLSRegulus Therapeutics2.1131 of 5 stars$1.24-3.1%$10.80+771.0%+3.3%$81.22MN/A-1.1630FBIOFortress Biotech2.7697 of 5 stars$1.87-2.1%$13.67+630.8%-2.1%$51.62M$62.50M-0.61170SABSSAB Biotherapeutics3.2177 of 5 stars$3.53-0.8%$12.40+251.3%-38.8%$32.58M$2.24M0.00140CRISCuris2.3129 of 5 stars$3.29+3.5%$23.00+599.1%-70.5%$27.87M$10.02M-0.4260 Related Companies and Tools Related Companies XOMA Alternatives Vanda Pharmaceuticals Alternatives Verastem Alternatives Sangamo Therapeutics Alternatives Lexicon Pharmaceuticals Alternatives Achieve Life Sciences Alternatives Regulus Therapeutics Alternatives Fortress Biotech Alternatives SAB Biotherapeutics Alternatives Curis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AGEN) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
